Your session is about to expire
← Back to Search
Statins
XueZhiKang (XZK) for Lipid Disorder
Phase 1
Waitlist Available
Research Sponsored by Luye Pharma Group Ltd.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 days
Awards & highlights
Summary
The objective of this study is to compare laboratory tests profiles of a botanic drug XueZhiKang (XZK) 300 mg capsules versus a marketed drug Lovastatin 20 mg tablets in healthy male volunteers between 18 and 50 years of age.
Eligible Conditions
- Lipid Disorder
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 12 days
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 days
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
AUC for the Pharmacokinetics (PK) of XZK
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: XueZhiKang (XZK)Experimental Treatment1 Intervention
XueZhiKang (XZK) 1200 mg
Group II: LovastatinActive Control1 Intervention
Lovastatin 20 mg
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
XueZhiKang
2015
Completed Phase 4
~80
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Luye Pharma Group Ltd.Lead Sponsor
64 Previous Clinical Trials
9,743 Total Patients Enrolled
Simon LI, M.D.Study ChairLuye Pharma
Share this study with friends
Copy Link
Messenger